Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HER2+ mCRC patients with exon 20 R784G substitution mutation do not respond to the cetuximab therapy.

Journal of cellular physiology - 1 Aug 2019

Gharib Ehsan, Salmanipour Reza, Nazemalhosseini Mojarad Ehsan, Yaghoob Taleghani Mohammad, Sarlak Saharnaz, Malekzade-Moghani Mona, Nasrabadi Parinaz Nasri, Meiary Mohammad Amin, Asadzadeh Aghdaei Hamid, Zali Mohammad Reza

Abstract excerpt

The human epidermal growth factor 2 (HER2) gene undergoes various mutations that could alter its activity or respond to the antibody therapies. Cetuximab, a known anti-EGFR monoclonal antibody (mAB), is widely administered in metastatic colorectal cancer (mCRC) cases. Here we identified mCRC patients who did not respond to cetuximab (500 mg/m2 , q2w) after fluoropyrimidine/oxaliplatin regimen failure. Tumor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Antineoplastic Agents, Immunological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to Cetuximab

Share to Colorectal Neoplasms

Share to Disease-Free Survival

Share to Drug Resistance, Neoplasm

Share to Erb-b2 Receptor Tyrosine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 30549033
DOI: 10.1002/jcp.27984
PMCID: PMC13483277

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HER2+ mCRC patients with exon 20 R784G substitution mutation do not respond to the cetuximab therapy.PMID 30549033Read ↗

HER2 targeted therapy in colorectal cancer: New horizons.Semantic proximity Read ↗

Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance.Semantic proximity Read ↗

Heterogeneous clinical and pathological landscapes of HER2 positive colorectal cancer.Semantic proximity Read ↗

EGFR S442 ectodomain mutation confers cetuximab resistance that can be overcome by ERBB2 blockade with trastuzumab-deruxtecan.Semantic proximity Read ↗

HER2 activating mutations are targets for colorectal cancer treatment.Semantic proximity Read ↗

KLF4 p.A472D Mutation Contributes to Acquired Resistance to Cetuximab in Colorectal Cancer.Semantic proximity Read ↗

Detection of K-ras Mutations in Predicting Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) Inhibitor in Patients with Metastatic Colorectal Cancer.Semantic proximity Read ↗

Molecular characterization of ERBB2-amplified colorectal cancer identifies potential mechanisms of resistance to targeted therapies: a report of two instructive cases.Semantic proximity Read ↗

Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical caseSemantic proximity Read ↗

HER2 in Colorectal Carcinoma: Are We There yet?Semantic proximity Read ↗

Case report outcome of cetuximab treatment in a metastatic colorectal cancer patient with novel KRAS P34R.Semantic proximity Read ↗

Response to Trastuzumab and Lapatinib in a Metastatic Colorectal Cancer Harboring HER2 Amplification and HER2 S310F Mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.